SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter-2 (SGLT-2) inhibitors (such as dapagliflozin, empagliflozin, ipragliflozin, and canagliflozin) are oral glucose-lowering medicines approved for the treatment of T2DM.